Mitozolomide
From Self-sufficiency
| File:Mitozolomide.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide | |
| Identifiers | |
| CAS Number | 85622-95-3 |
| ATC code | none |
| PubChem | CID 71766 |
| Chemical data | |
| Formula | C7H7ClN6O2 |
| Molar mass | 242.622 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.
Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]
References
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Chemotherapeutic agents
- Antineoplastic and immunomodulating drug stubs
